Rational targeting Cdc42 restrains Th2 cell differentiation and prevents allergic airway inflammation

BACKGROUND: Asthma is an allergic airway inflammation-driven disease that affects more than 300 million people worldwide. Targeted therapies for asthma are largely lacking. Although asthma symptoms can be prevented from worsening, asthma development can’t be prevented. Cdc42 GTPase has been shown to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Exp Allergy
Autors principals: Yang, Jun-Qi, Kalim, Khalid W., Li, Yuan, Duan, Xin, Nguyen, Phuong, Khurana Hershey, Gurjit K., Kroner, John, Ruff, Brandy, Zhang, Li, Salomonis, Nathan, Rochman, Mark, Wen, Ting, Zheng, Yi, Guo, Fukun
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6310654/
https://ncbi.nlm.nih.gov/pubmed/30307073
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cea.13293
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars